In:
European Journal of Haematology, Wiley, Vol. 98, No. 4 ( 2017-04), p. 363-370
Kurzfassung:
This study investigates whether achieving complete remission ( CR ) with undetectable minimal residual disease ( MRD ) after allogeneic stem cell transplantation (allo‐ SCT ) for chronic lymphocytic leukemia ( CLL ) affects outcome. Methods We retrospectively studied 46 patients transplanted for CLL and evaluated for post‐transplant MRD by flow cytometry. Results At transplant time, 43% of the patients were in CR , including one with undetectable MRD , 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression‐free survival ( P = 0.02) and attaining undetectable MRD , independently of the time of negativity, was the only factor that correlated with better overall survival ( P = 0.04). Conclusion Thus, achieving undetectable MRD status after allo‐ SCT for CLL is a major goal to improve post‐transplant outcome.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2017.98.issue-4
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
2027114-1
